Zymeworks rejects All Blue’s $773M offer as an ‘opportunistic’ public attacknews2022-05-20T14:53:19+00:00May 20th, 2022|FierceBiotech|
Not an ‘excellent outcome’ for Athersys stock as stem cell therapy misses endpoint in Japanese trialnews2022-05-20T13:45:41+00:00May 20th, 2022|FierceBiotech|
100% overall survival data for gene therapy fuel Rocket for flight to regulatorsnews2022-05-20T13:41:13+00:00May 20th, 2022|FierceBiotech|
Death triggers FDA hold on Foghorn blood cancer clinical trial, shrouding timing of data dropnews2022-05-20T10:15:54+00:00May 20th, 2022|FierceBiotech|
Bayer pulls plug on $670M CAR-T cell therapy pact with Atara in wake of patient deathnews2022-05-20T09:17:15+00:00May 20th, 2022|FierceBiotech|
Chutes & Ladders—Aquestive CEO heads for the exits while seizure med remains in regulatory limbonews2022-05-19T19:21:33+00:00May 19th, 2022|FierceBiotech|
Inceptor Bio to use $37M series A to nudge CAR-T toward clinic, establish manufacturing basenews2022-05-19T13:40:43+00:00May 19th, 2022|FierceBiotech|
Amgen celebrates 25 years of deCODE Genetics as partnership evolves from discovery to developmentnews2022-05-19T12:48:39+00:00May 19th, 2022|FierceBiotech|
Enanta sinks to multiyear low as phase 2b RSV trial flames outnews2022-05-19T10:45:46+00:00May 19th, 2022|FierceBiotech|
Nanobiotix scales down R&D plan, freezes hiring to close gap between cash runway and phase 3 datanews2022-05-19T09:52:20+00:00May 19th, 2022|FierceBiotech|
